Reflecting the Center's mission to use cutting edge research in basic and clinical sciences to advance the care of individuals living with BRCA1 and BRCA2 mutations, grants are focused on innovative cancer research projects. Investigators who have already received peer-reviewed funding for their proposed projects will not be eligible for this award.
The scientific objective of the Basser Center for BRCA includes the funding of research projects related to BRCA1/2 ranging from basic science to clinical/translational research. Collaborative projects are strongly encouraged. Please note, the science must have relevance to the study of BRCA1/2 to be considered.
The Basser Center has the unique opportunity to catalyze the assembly of teams to change the paradigm of discovery, innovation, and care for issues related to BRCA1 and BRCA2 mutations. Germline mutations in BRCA1 and BRCA2 significantly increase the risk of breast and ovarian cancer and also are associated with prostate cancer and pancreatic cancer. Towards this end, the Basser Center is seeking applications for two types of grants:
The Basser Internal Funding Program is currently closed and no longer accepting applications.
The Basser Center for BRCA at Penn Medicine's Abramson Cancer Center announces the 2015 Basser External Research Grant Program, which focuses on projects that have the potential to advance the care of individuals living with BRCA1 and BRCA2 mutations. Research grant applications in basic science, prevention, early detection, or targeted therapeutics and relevant to the study of BRCA1/2 will be considered. Basser Innovation Awards include three $100,000 one-year high-risk idea projects. Grants that demonstrate a potential for translation into clinical practice will be prioritized for funding.